OVP, QualiMed ink deal on assistance for COVID treatment drug
The Office of the Vice President (OVP), under the leadership of VP Leni Robredo, and the QualiMed Health Network on Monday signed a Memorandum of Agreement (MOA) on providing assistance for referred patients prescribed with Molnupiravir, an oral pill for the treatment of mild to moderate cases of COVID-19.
Under the MOA, the OVP will issue a guarantee letter (GL) under its special medical assistance program to any qualified patient referred by a volunteer doctor in the OVP's Bayanihan E-Konsulta (BEK) and is further assessed and prescribed Molnupiravir by QualiMed facilities.
Usec. Philip Dy signed for the OVP, while Jaime E. Ysmael, President and CEO, and Margaret A. Bengzon, Group COO, signed for the QualiMed Health Network.
The Food and Drug Administration (FDA) has issued a Compassionate Special Permit (CSP) for the use of Molnupiravir, developed by Merck (known as MSD outside of the US and Canada) and Ridgeback Biotherapeutics, to several hospitals. This includes QualiMed facilities like QualiMed San Jose Del Monte in Bulacan and QualiMed Manila within the PGH Compound, both located in the NCR Plus area.
The first shipment of Molnupiravir arrived in the Philippines, last November 17, the first in Southeast Asia.